Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Thorac Oncol. 2020 Dec 8;16(3):419–427. doi: 10.1016/j.jtho.2020.11.021

Figure. 5. Independence of the compound mutation signature from PD-L1 in predicting ICB treatment response.

Figure. 5.

A). PD-L1 expression levels in NSCLC patients with different mutation signatures.

B). OS levels of patients stratified according to their PD-L1 expression levels and mutation signature status. PL-NC: PD-L1 level low(<1%), no compound signature; PH-NC, PD-L1 high (≥1%), no compound signature; PL-C, PD-L1 low (<1%), compound signature; PH-C, PD-L1 high (≥1%,) compound mutation signature. P-values calculated by use of unpaired t-test (A) or logrank test (B).